Should You Investigate Cantel Medical Corp. (NYSE:CMD) At US$66.92?HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Should You Investigate Cantel Medical Corp. (NYSE:CMD) At US$66.92?Simply Wall StSimply Wall St.January 8, 2020ReblogShareTweetShareView photosCantel Medical Corp. (NYSE:CMD), which is in the medical equipment business, and is based in United States, received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$78.03 at one point, and dropping to the lows of US$66.92. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Cantel Medical's current trading price of US$66.92 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at Cantel Medical’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Check out our latest analysis for Cantel Medical What's the opportunity in Cantel Medical?The stock seems fairly valued at the moment according to my valuation model. It’s trading around 3.5% below my intrinsic value, which means if you buy Cantel Medical today, you’d be paying a reasonable price for it. And if you believe the company’s true value is $69.37, then there’s not much of an upside to gain from mispricing. In addition to this, Cantel Medical has a low beta, which suggests its share price is less volatile than the wider market.Can we expect growth from Cantel Medical?NYSE:CMD Past and Future Earnings, January 8th 2020MoreFuture outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. In Cantel Medical’s case, its earnings over the next year are expected to double, indicating an incredibly optimistic future ahead. This should lead to stronger cash flows, feeding into a higher share value.What this means for you:Are you a shareholder? CMD’s optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value?Are you a potential investor? If you’ve been keeping tabs on CMD, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it’s worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Cantel Medical. You can find everything you need to know about Cantel Medical in the latest infographic research report. If you are no longer interested in Cantel Medical, you can use our free platform to see my list of over 50 other stocks with a high growth potential.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoIndia Stocks Extend Slide, Heading for Worst Week in Four YearsBloombergMost face masks won’t protect you from the coronavirusYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoWhy BE Group AB (publ) (STO:BEGR) Is A Dividend RockstarSimply Wall St.Richard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinancePersonal loans growth rate rises, impacts retailersYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance